A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · B-cell Acute Lymphoblastic Leukemia · Pediatric Cancer · Pediatric ALL, Relapsed · Pediatric ALL · Pediatric ALL, B Cell · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Pediatric AML · R/R AML · R/R B-cell ALL
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 30 (planned)
- Started
- Dec 2026
- Main results expected
- Apr 30, 2030
- Fully finished
- Sep 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: From first dose of study drug to 30 days after last dose; up to approximately 12 months in cohort 1 and 4 months in cohort 2.
Part 1: Recommended Dose for Expansion (RDFE) of Sonrotoclax
Measured over: From first dose through end of Cycle 1 (each cycle is 28 days); approximately 2 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07770698 · record last updated 2026-10-26 · checked 2026-11-09 15:42 UTC